Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

download Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

of 15

Transcript of Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

  • 7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

    1/15

    Ucl }loiagag`

    }lzli}jc i`lgei2 f}kojkgu}kddle u}aidz uk

    lffljuavl ~}k`}ioz

    ^}lzlgule mq2 ^al}}l Dijl}ul

    Cliduc Ievazk} + Oiul}gid ige

    Glpmk}g Cliduc ige G|u}auakg ^}k`}ioOigi`l} ag If}aji

    Ecihi$ :}e Oiq $ =>9=

  • 7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

    2/15

    Mijh`}k|ge ige okuaviuakg fk} ucaz ~}lzlguiuakg

    Lvaelgjl fk} ucl lffajijqkf jidja|o z|~~dlolguiuakg uk }le|jl }azh

    kf ~}lljdio~zai az zu}kg` @lgl}iule f}ko }igekoarle jkgu}kddle u}aidz ag o|dua~dl zluuag`z

    Fa}zu agul}vlguakgz zckpg uk ml lffljuavl fk} ~}lvlguakg

    ^i}uaj|di}dq }ldlvigu ag jkgulsu pcl}l lol}`lgjq kmzulu}aj ji}l

    oiq ml plih'

    Zqzuloiuaj }lvalpz uk ls~dk}l kvl}idd ao~iju fk}o mizaz kf

    `|aeldaglz gkp elvldk~le mq PCK

    I g|oml} kf ~}ijuajid y|lzuakgz }loiag$ igzpl}z uk pcajc pk|de

    zu}lg`uclg ucl ji~ijauq uk elza`g ige ao~dlolgu ~}k`}ioz

    Lvaelgjl mizl pk|de ml zu}lg`uclgle mq~}k`}io lvid|iuakgz$

    jko~dlolgui}q uk uciu `lgl}iule ag }igekoarle u}aidz

  • 7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

    3/15

    Lsul}gid Fijuk}z

    Zkjak/j|du|}id

    Uljcgajid Ljkgkoaj

    ^kdauajid

    ^}kvazakg

    Y|iguauq

    Y|idauq

    Uaoldaglzz

    \~uihl

    Ipi}lglzz

    Iuuau|el

    Ijjlzzamadauq

    \uadariuakg

    \~uihl ( Hgkpag` mlglfauz &

    ckp uk |zl ( Lsul}gid

    okuaviuakg

    Ao~iju

    G|u}auakgid Glle ( Jkvl}i`l ( \uadariuakg

    Ao~iju kf agul}vlguakgz el~lgeigu kg o|dua~dl fijuk}z

    Jkgulsu|iddq }ldlvigu ~ijhi`l kf agul}vlguakgz

    Jkvl}i`l

    ^}kvazakg (

    \~uihl mq uckzl ag

    glle

    GLLE

  • 7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

    4/15

    Kmbljuavlz kf ucaz ~}lzlguiuakg

    Uk ls~dk}l zkol uk~ajz }ldiule uk jidja|o

    z|~~dlolguiuakg uciu pk|de ml zu}lg`uclgle mq

    ieeauakgid makdk`ajid ige ao~dlolguiuakg }lzli}jc

    Uk agauaiul i eazj|zzakg kg i~~}k~}aiul piqz uk okvl

    ~}k`}ioz fk}pi}e pcadl ipiauag` ucaz ieeauakgid

    lvaelgjl

    Uk |~eiul kg zkol ievigjlz mlag` oiel kg ucl

    }lzli}jc i`lgei

  • 7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

    5/15

    Zkol kf ucl jciddlg`lz uciu pl civl zllg fk} AFI

    ~}k`}ioz dahldq uk ml zaoadi} fk} Jidja|o

    z|~~dlolguiuakg ~}k`}ioz

    Eloige zael2

    Jkguiju pauc pkolg oiq ml`ag kgdq diul ag ~}l`gigjq

    A}}l`|di} jkguiju oiq daoau lffljuavl jkvl}i`l$

    k~~k}u|gaualz fk} lgjk|}i`lolgu uk jko~dq ^kzzamdl azz|lz pauc |~uihl ige jko~daigjl

    Z|~~dq zael2

    M|e`lu iddkjiuakg ekgk} el~lgelgjq

    ^kk}dq f|gjuakgag` z|~~dq jciagz

  • 7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

    6/15

    Zkol kf ucl jciddlg`lz uciu pl civl zllg fk} AFI

    ~}k`}ioz dahldq uk ml zaoadi} fk} Jidja|o

    z|~~dlolguiuakg ~}k`}ioz

    Eloige zael2

    Jkguiju pauc pkolg oiq ml`ag kgdq diul ag ~}l`gigjq

    A}}l`|di} jkguiju oiq daoau lffljuavl jkvl}i`l$

    k~~k}u|gaualz fk} lgjk|}i`lolgu uk jko~dq ^kzzamdl azz|lz pauc |~uihl ige jko~daigjl

    Z|~~dq zael2

    M|e`lu iddkjiuakg ekgk} el~lgelgjq

    ^kk}dq f|gjuakgag` z|~~dq jciagz

    Iduck|`c pldd }ljk`garle$ oigq kf uclzlazz|lz civl gku mllg iely|iuldq iee}lzzle

    fk} AFI ~}k`}ioz' Gkp pl zck|de2

    Ivkae Ji ~}k`}ioz dahldq uk z|ffl} f}ko

    zaoadi} z|~~dq ige eloige/zael ~}kmdloz

    Uihl ievigui`l uk }lglp lffk}uz uk

    zu}lg`uclg AFI ige Ji ~}k`}ioz

    zao|duiglk|zdq

  • 7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

    7/15'2'

    OAz Oiul}gid ige Glkgiuid Cliduc ige

    G|u}auakg ^}k`}ioOAz Oiul}gid ige Glkgiuid Cliduc ige

    G|u}auakg ^}k`}io

    Ieeauakgid jciddlg`lz

    Aelguafajiuakg kf ~k~|diuakgz pauc dkp jidja|oaguihlz ag jkgulsu pcl}l ealui}q eiui az$ iu mlzu$

    zji}jl

    Jidja|o z|~~dlolguz oiq agcamau imzk}~uakg kfa}kg$ el~lgeag` kg ekzl ige a}kg zk|}jl

    Jidja|o ige A}kg zci}l `izu}kagulzuagid zael lffljuz

    uciu oa`cu daoau iecl}lgjl

  • 7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

    8/15'2'

    OAz Oiul}gid ige Glkgiuid Cliduc ige

    G|u}auakg ^}k`}ioOAz Oiul}gid ige Glkgiuid Cliduc ige

    G|u}auakg ^}k`}io

    Zkol dlzzkgz dli}gu ige jkookg

    zlgzl }lz~kgzlz uk uclzl jciddlg`lz

    Agulgzl ige lffljuavl u}iagag` padd ml }ly|a}le fk} cliduc

    ji}l ~}kvael}z

    Okuaviuakg uk ijjl~u ige ao~dlolgu ~}k`}io

    lffljuavldq$ agjd|eag` z|~~dq oigi`lolgu ige

    jkoo|gajiuakg pauc ~}l`gigu pkolg

    Lffljuavl mlcivak|} jcig`l jkoo|gajiuakg

    ]ly|a}lz ig |gel}zuigeag` kf ucl mi}}al}z ige

    fijuk}z uciu pk|de fijadauq |~uihl ige iecl}lgjl

  • 7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

    9/15

    '2'

    OAz Oiul}gid ige Glkgiuid Cliduc ige

    G|u}auakg ^}k`}ioOAz Oiul}gid ige Glkgiuid Cliduc ige

    G|u}auakg ^}k`}io

    OAz oiul}gid ige glkgiuid cliduc ige g|u}auakg agauaiuavlz

    @kid2 Elvldk~$ ao~dlolgu ige lvid|iul elokgzu}iuakg ~}kbljuz$

    ag dagl pauc jk|gu}q ~}ak}aualz ige j|}}lgu ijuavaualz$ ukagj}lizl ucl jkvl}i`l ige y|idauq kf jkoo|gauq mizle

    agul}vlguakgz uk ao~}kvl oiul}gid ige glkgiuid z|}vavid ige

    cliduc$ lgz|}ag` ucl agjd|zakg kf i~~}k~}aiul ige aggkviuavl

    g|u}auakg ige z~ljafajiddq oaj}kg|u}algu agul}vlguakgz'

    5 Fkj|z jk|gu}alz2

    Lucak~ai

    Hlgqi

    Zlgl`id Ga`l}

  • 7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

    10/15

    '2'

    OAz Oiul}gid ige Glkgiuid Cliduc ige

    G|u}auakg ^}k`}ioOAz Oiul}gid ige Glkgiuid Cliduc ige

    G|u}auakg ^}k`}io

    OA aelguafale ucaz iz i j}auajid k~~k}u|gauq uk agvlzu ag

    }lzli}jc }ldiule uk jidja|o z|~~dlolguiuakg fk}

    ~}l`gigu pkolg

    Oiag Kmbljuavl 2 Elvldk~ ige ulzu lvaelgjl/mizle zu}iul`alz fk}

    ao~dlolguag` jidja|o z|~~dlolguiuakg e|}ag` ~}l`gigjq fk} ucl

    ~}lvlguakg kf ~}l/ljdio~zai ige ljdio~zai ag zluuag`z pauc dkp }iulz kf

    ealui}q jidja|o aguihl ige plih cliduc zqzuloz'

    \duaoiul K|ujkol2 ^kdajq oihl}z$ ~}k`}io elvldk~l}z ige oigi`l}z civl

    ijj|}iul ige jko~dlul agfk}oiuakg kf ucl ~kulguaid mi}}al}z ige fijuk}z

    uciu pk|de fijadauiul ao~dlolguiuakg ige ijjl~uigjl kf jidja|o ige AFI

    z|~~dlolguiuakg ~}k`}ioz ige |zl uciu agfk}oiuakg uk elza`g lffljuavl

    ~}k`}ioz

    ^i}ugl}2 OA$ Jk}gldd \gavl}zauq ige ucl ~i}ugl}z agvkdvle ag OAz

    elokgzu}iuakg ~}kbljuz ag Lucak~ai #Oagazu}q kf Cliduc$ Lok}q \gavl}zauq!

    ige Hlgqi #Oagazu}q kf Cliduc$ IO]LF ige ]KGUK Agul}giuakgid!

  • 7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

    11/15

    ^}kblju uk ml ao~dlolgule ag = ~cizlz uk

    iee}lzz z~ljafaj jciddlg`lz fk} ~}k`}io elza`g2

    $ =>>6'

    Jciddlg`l 92 Dkp |~uihl kf AFI$ dkp igulgiuid ji}l jkvl}i`l ige diul ige agf}ly|lgu

    jkguiju pauc cliduc ji}l zqzulo

    ]lzli}jc kmbljuavl 92 Uk aelguafq ig k~uao|o eldavl}q ~diufk}o fk} Ji ige AFI

    z|~~dlolguiuakg mizle kg mi}}al}z ige fijadauiuag` fijuk}z fk} eldavl}q$ eloige ige

    iecl}lgjl$ ige eiui kg cliduc zqzulo ji~ijauq fk} lffljuavl oigi`lolgu ige

    eldavl}q kf z|~~dalz'

    Jciddlg`l =2 ^kk} jko~daigjl pauc AFI z|~~dlolguiuakg j|}}lgudq$ ~kulguaiddq `}liul}

    }azhz pauc ieeauakg kf jidja|o #di}`l}$ ieeauakgid uimdlu$ zael lffljuz luj'!

    ]lzli}jc kmbljuavl =2 Jkddlju ige izzaoadiul agfk}oiuakg kg ucl ~l}z~ljuavlz kf

    cliduc ji}l ~}kvael}z ige mlglfajai}alz uciu az gllele uk elza`g lffljuavl mlcivak|}

    jcig`l jkoo|gajiuakg uk z|~~k}u eloige$ ao~dlolguiuakg$ |uadariuakg$ ige

    iecl}lgjl fk} Ji ige AFI z|~~dlolguiuakg']lzli}jc kmbljuavl :2 Elza`g okeldz fk} eldavl}q ige ~}kokuakg kf Ji ige AFI

    z|~~dlolguz ag ~}l`gigjq' Aelguafq }loiagag` y|lzuakgz kg z|~~dlolgu eldavl}q$

    u}iagag`$ olzzi`lz$ ige oiul}aidz uciu zck|de ml ulzule ag ~adku zu|eq |zag` ~}kjlzz

    ige k|ujkol lvid|iuakg ige elvldk~ ~}kukjkdz fk} ~adku ~}kblju

    '2'

  • 7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

    12/15

    I zio~dag` kf ucl azz|lz uciu padd ml iee}lzzle2

    $ =>>6'

    Z~ljafajiuakg kf Ji ige AFI z|~~dlolgu fk}o|diuakg

    #agul}ijuakgz$ ekzag`$ ~ijhi`ag`$ jkzu$ luj! Fk}ljizuag` ige oigi`lolgu ~dig fk} lgz|}ag` iely|iul

    eazu}am|uakg ige zukjhag` kf z|~~dalz

    Elvldk~olgu kf ~}kukjkdz ige jcljhdazuz fk} agul`}iuag` Ji ige

    AFI z|~~dlolguiuakg aguk IGJ zl}vajlz iu idd }ldlvigu dlvldz kf

    ucl cliduc zqzulo

    MJJ zu}iul`alz ige oiul}aidz fk} zuao|diuag` eloige iokg`

    ~kulguaid mlglfajai}alz$ ige okuaviuag` ige z|zuiagag` iecl}lgjl

    uk z|~~dlolguz

    U}iagag` fk} cliduc ji}l ~}kvael}z ag z|~~dlolgu eldavl}q igejkoo|gajiuakg

    U}iagag` fk} z|~l}vazakg ige okgauk}ag` kf ao~dlolguiuakg

    '2'

  • 7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

    13/15

    ^cizl = padd agjd|el ~adku ulzuag` ucl glp

    eldavl}q okeld ag mkuc jk|gu}alz

    $ =>>6'

    Kmbljuavl 92 Ulzu okeldz elvldk~le ag ^cizl 9 mq ao~dlolguag` Ji ige AFIz|~~dlolguiuakg paucag ucl cliduc zqzulo ag i zoidd g|oml} kf ~}kblju

    zaulz zldljule ag jkgb|gjuakg pauc OKC ag Hlgqi ige Lucak~ai'

    Kmbljuavl =2 Lvid|iul ucl ao~dlolguiuakg ~}kjlzz ige lffljuavlglzz kf ucl

    okeld zu}iul`alz'

    Kmbljuavl :2 ]lfagl okeldz ige oihl }ljkoolgeiuakgz fk} ao~}kvag`

    ao~dlolguiuakg ige lffljuavlglzz'

    Kmbljuavl 52 Eazzloagiul }lz|duz uk ~}kvael ~kdajq oihl}z$ ~}k`}ioelvldk~l}z ige cliduc ji}l ~}kvael}z pauc agfk}oiuakg gllele kg ucl

    vid|l kf ige mlzu ~}ijuajlz fk} ao~dlolguiuakg kf Ji ige AFI

    z|~~dlolguiuakg e|}ag` ~}l`gigjq'

    '2'

  • 7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

    14/15

    Uaoldagl ige zkol ao~dajiuakgz fk} j|}}lgu ~}k`}io

    lffk}uz

    Ucl OA ~}kblju padd uihl uaol

    Zck|de gku ao~lel ~}k`}io elvldk~olgu ag kucl}

    jk|gu}alz

    ^}k`}ioz ag idd jk|gu}alz zck|de agvlzu ag ucl fk}oiuavl }lzli}jc

    ige agfk}oiuakg jkddljuakg uciu padd lgz|}l i~~}k~}aiul

    ~}k`}io elza`g ag ucla} jkgulsu2

    Aggkviuavl idul}giuavlz fk} eldavl}q #~i}uaj|di}dq af AFI

    ~}k`}ioz civl gku mllg z|jjlzzf|d!

    Aelguafajiuakg ige }lzkd|uakg kf fk}ljizuag` ige z|~~dq jciag

    azz|lz

    Lffljuavl u}iagag` fk} cliduc ji}l ~}kvael}z

    ]ldlvigu ige lffljuavl jkoo|gajiuakg uk ~}kokul ~}k`}io

    |~uihl ige |uadariuakg mq ~}l`gigu pkolg

  • 7/31/2019 Lacerte_The Remaining Research Agenda_From Controlled Trials to Effective Programs

    15/15